ALK | Allergy solutions for life
ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

allergy_solutions_for_life

News

  • Post date
    08/12/2020
    Six-month interim report (Q2) 2020
  • Post date
    08/05/2020
    Release date of six-month interim report (Q2) 2020 for ALK and audio cast
  • Post date
    05/20/2020
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    05/11/2020
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    05/06/2020
    Three-month interim report (Q1) 2020
  • Post date
    04/28/2020
    Release date of three-month interim report (Q1) 2020 for ALK and audio cast
  • Post date
    04/20/2020
    ALK announces Health Canada approval of ITULATEK SLIT-tablets for the treatment of tree pollen allergy
  • Post date
    03/19/2020
    Grant of share options and performance shares to members of the Board of Management and key employees
  • Post date
    03/11/2020
    Annual General Meeting in ALK-Abelló A/S held on 11 March 2020

Seasonal allergy symptoms can be confused with COVID-19

Therefore allergy symptoms should be kept under the best possible control. Watch Dr Glenis Scadding's expert advise in respect of seasonal allergies and COVID-19.

seasonal_allergic_rhinitis_in_relation_to_covid-19

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.